Promacta and Doptelet drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Promacta (eltrombopag olamine) and Doptelet (avatrombopag maleate). Common drug interactions include platelet count decreased among females and infusion site swelling among males.

The phase IV clinical study analyzes what interactions people have when they take Promacta and Doptelet. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Promacta?

Promacta has active ingredients of eltrombopag olamine. It is often used in idiopathic thrombocytopenic purpura (itp). eHealthMe is studying from 17,758 Promacta users. Check the latest studies of Promacta.

What is Doptelet?

Doptelet has active ingredients of avatrombopag maleate. eHealthMe is studying from 1,389 Doptelet users. Check the latest studies of Doptelet.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

30 people who take Promacta and Doptelet together, and have interactions are studied.

Promacta and Doptelet drug interactions.

What are the common drug interactions of Promacta and Doptelet, by gender? *:

female:

Platelet count decreased
Platelet count increased
Headache (pain in head)
Eye pruritus (eye itching)
Confusional state
Drug ineffective
Lacrimation increased
Nausea (feeling of having an urge to vomit)
Fatigue (feeling of tiredness)
Abdominal pain upper

male:

Infusion site swelling
Drug ineffective
Central nervous system lesion (an abnormality in tissue of brain or spinal cord)
Death
Diplopia (double vision)
Dizziness
Dysstasia (difficulty in standing)
Eye haemorrhage (bleeding in the eye)
Liver disorder (liver diseases)
Platelet count decreased

What are the common drug interactions of Promacta and Doptelet, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Abdominal pain upper
Aortic stenosis (obstruction to the outflow of blood from the left ventricle into the aorta)
Chest pain
Fatigue (feeling of tiredness)
Platelet count increased
Pneumonia
Pyrexia (fever)
Renal vein thrombosis (blood clot in renal vein)
Thrombocytosis
Vaginal haemorrhage (vaginal bleeding)

50-59:

Blindness
Death
Eye haemorrhage (bleeding in the eye)

60+:

Platelet count decreased
Confusional state
Adverse reaction
Fall
Fatigue (feeling of tiredness)
Limb discomfort (discomfort in leg)
Pain in extremity
Peripheral swelling
Polycythaemia (proportion of blood volume that is occupied by red blood cells increases)
Eye pruritus (eye itching)

What are the existing conditions these people have? *

Thrombocytopenia (decrease of platelets in blood): 5 people, 16.67%
Primary Myelofibrosis (primary disorder of the bone marrow): 3 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Promacta and Doptelet?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously